About Afimmune

Afimmune, headquartered in Dublin, Ireland, is a drug discovery and development company working on new medicines to improve the quality of life for people with diseases for which existing therapies are ineffective or unsafe. Afimmune has assets in various stages of clinical and pre-clinical development. Afimmune pipeline

Latest News

June 3, 2021

Afimmune Announces Positive Data with Epeleuton from Preclinical Atherosclerosis Studies

Data show large decreases in atherosclerotic plaque following treatment with epeleuton Dublin, Ireland, 3rd June 2021 – Afimmune, a clinical stage drug discovery company focused on […]
September 23, 2020

Afimmune Initiates Epeleuton Phase IIb TRIAGE Study in Patients With High Triglycerides and Type 2 Diabetes

Data from Phase IIa show potent effect of Epeleuton on Triglyceride and HbA1C levels Dublin, Ireland, 23rd September 2020 – Afimmune, a clinical stage drug discovery […]

Join our mailing list

Contact us

t: +353 1 2946380 e: [email protected]

Latest Media

December 15, 2020

Epeleuton and the potential of next generation Omega-3 fatty acids is discussed in the December 2020 edition of Pharmaceutical Market Europe

The article can be found below.   Treatment and prevention of cardiovascular disease The potential of next generation omega-3 fatty acids In 2019 approximately 17.3 million […]